Overview

A Mass Balance and Pharmacokinetics Study of 14C-Labeled Poziotinib in Cancer Patients Suitable for Treatment With Poziotinib

Status:
Terminated
Trial end date:
2020-06-17
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine routes of excretion and single-dose PK parameters for poziotinib in patients with solid tumors with EGFR or HER2 mutations or EGFR/HER2 overexpression/amplification.
Phase:
Phase 1
Details
Lead Sponsor:
Spectrum Pharmaceuticals, Inc